2023 was another eventful year for the Nordic healthcare stocks with plenty of opportunities amid an index loss of 20%. The best performers were, not
Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider
Despite a revenue in H1 22/23 of DKK 0.3 million (DKK 0.2 million) CS Medica maintains the expectation for the year’s revenue growth of 120-130%
In the Danish Biotech Weekly, we give you insights into the Danish biotech stocks. We follow the small and established ones at home and abroad.
CS Medica has achieved positive results of a clinical study with its pain patch with CBD. With clinical proof of efficacy, the possibilities are fot
In the past week several companies announced updates to their clinical trial updates that usually acts as price trigger events for the share price. Furthermore,
The past week Gubra A/S went public on the main stock exchange in Copenhagen, raising 500 MDKK. The share price for Gubra is currently trading
CS Medica has entered into a joint venture and investment agreement with Chinese Inner Mongolia RongShi Hi-Tech Co. Ltd. regarding production of CS Medica’s CANNASEN
Danish biotech companies had a tough time in 2022, with Kapital Partners’ Nordic Healthcare index falling by 48% due to greater risk aversion among investors,
Developments during the week at the Nordic growth exchanges The Kapital Partner Nordic Growth Exchanges (KPNGX) index fell 2.3% last week. The Swedish S30 index
Kapital Partner performs or has within the last 12 months performed corporate finance, market relations, investor relations, Certified Adviser or other advisory activities for the following listed companies: NORD.investments, Biosergen, InterMail, Pila Pharma, Hypefactors, Curasight, Evaxion, Re-Match, Audientes, Mdundo.com, Nexcom.
Del indlægget på sociale media eller på email.